

# Curriculum Vitae - Prof. Dr. med. Dr. rer. nat. Ghazaleh Tabatabai

## Personal Data

Title	Prof. Dr. med. Dr. rer. nat.
First name	Ghazaleh
Name	Tabatabai
Current position	Full Professor (W3, permanent)
Current institution(s)/site(s), country	Department of Neurology and Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany
Identifiers/ORCID	0000-0002-3542-8782

## Qualifications and Career

Stages	Periods and Details
Degree program	<b>1993 - 2000</b> Medicine (M.D.), Heinrich Heine University Düsseldorf
Doctorate	<b>2005 - 2009</b> Doctor of Natural Sciences (Dr. rer. nat.), Doctoral program Graduate Training Center for Neuroscience Tübingen, Grade: <i>summa cum laude</i> . <b>1999 - 2002</b> Doctor of Medicine (Dr. med), Heinrich Heine University Düsseldorf. Grade: <i>summa cum laude</i>
Stages of academic/professional career	<b>2023 - 2026</b> Managing Clinical Director, Hertie Center for Neurology, University Hospital Tübingen <b>2022 - 2024</b> Deputy Director (clinic), Comprehensive Cancer Center Tübingen-Stuttgart <b>2022 - 2025</b> Chair of the structured DIAMOND mentoring program of the Neuro-Oncology Association for mentee in Germany, Austria and Switzerland <b>Since 12/2019</b> Chair, Department of Neurology and Interdisciplinary Neuro-Oncology University Hospital Tübingen, Hertie Institute for Clinical Brain Research, University of Tübingen <b>2019 - 2020</b> Vice Dean, Medical Faculty Tübingen <b>2018 - 2020</b> Dean of Study Affairs, Molecular Medicine, Medical Faculty Tübingen <b>2016 - 2018</b> Deputy Dean of Study Affairs, Molecular Medicine, Medical Faculty Tübingen <b>2017 - 2019</b> Certificate of Advanced Studies "Systemic Management in Health Care", University of St. Gallen, Switzerland <b>2014 - 2019</b> Head, Division of Interdisciplinary Neuro-Oncology, Departments of Neurology & Neurosurgery University Hospital Tübingen <b>Since 2014</b> Full Professor W3, Neuro-Oncology, University of Tübingen <b>Since 2014</b> Research Group leader, Hertie Institute for Clinical Brain Research, University of Tübingen <b>2009-2014</b> Research Group leader, Center for Neuroscience Zurich, ETH & University of Zurich

	<b>2009-2014</b>	Department of Neurology, University Hospital Zurich, Switzerland
	<b>2011-2012</b>	Certificate of Advanced Studies "Clinical Trials Management", University of Zurich, Switzerland
	<b>2012</b>	Habilitation, Venia legend, Neurology, University of Zurich
	<b>2009</b>	Board certification, Neurology, Landesärztekammer Baden-Württemberg
	<b>2003-2009</b>	Residency Neurology, University Hospital Tübingen
	<b>2001-2003</b>	Residency Neuropathology, University Hospital Zurich
	<b>2000-2001</b>	Internship, Elective rotation in Neurology at Harvard Medical School, Boston, USA

### Activities in the Research System

#### *Committees and (inter)national boards (selection)*

- 2024-2028 Chair, Expert Evaluation Committee (Fachkollegium) 206 Neuroscience, Deutsche Forschungsgemeinschaft
- 2020-2028 Member, Expert Evaluation Committee (Fachkollegium) 206 Neuroscience, Deutsche Forschungsgemeinschaft
- 2022-2024 Scientific Evaluation Committee, Institut National du Cancer, France
- Since 2021 CNS Tumors Faculty Group, European Society for Medical Oncology
- 2018-2022 Guideline Committee, European Association of Neuro-Oncology
- Since 2017 Executive Board, Center for Personalized Medicine Tübingen
- 2016-2024 Executive Board, Comprehensive Cancer Center Tübingen
- 2015-2020 Neuro-Oncology Committee, World Federation of Neurosurgical Societies

#### *Coordination of joint funding programs and clinical trials*

- Since 2023 International Coordinator/Lead Principal Investigator, CV-GBLM001 trial, phase 1 (NCT05938387), Sponsor: CureVac
- Since 2021 Sponsor delegate/Principal investigator, Investigator-initiated phase 1 trial NOA26/IT-PD1 (NCT05112549), Sponsor: University Hospital Tübingen
- 2021-2025 Sponsor delegate/Principal investigator, Investigator-initiated phase 1 trial GlioXS15 (NCT04842513), Sponsor: University Hospital Tübingen
- 2017-2024 Spokesperson/Lead Principal Investigator, Else Kröner-Forschungskolleg Tübingen, "Acquired resistance to therapy in solid tumors" (two funding periods)

#### *Ad hoc referee for scientific journals (selection)*

Acta Neuropathologica, Annals of Oncology, Brain, Clinical Cancer Research, European Journal of Cancer, Molecular Cancer, Neuro-Oncology, Nature Medicine, Lancet Oncology

#### *Ad hoc referee for funding agencies and organizations (selection)*

Cancer Research UK (GB), Yorkshire Cancer Center (GB), Oncosuisse (CH), Institut National du Cancer (F), Agence Nationale de la Recherche (F), ZonMW (Niederlande), Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.

### Supervision of Researchers in Early Career Phases

- **Supervision of Postdoctoral Researchers and Clinician Scientists**

Supervision of 3 Postdoctoral researchers (2 female, 1 male), 6 Clinician Scientists (3 female, 3 male)

- **Supervision of PhD students**

4 PhD students completed (3 x Dr. rer. nat, summa cum laude / 1 x Dr. sc. nat, magna cum laude, 3 female, 1 male), 4 PhD students currently ongoing (2 female, 2 male).

- **Supervision of Medical Students**

2 MD completed with experimental work in the lab (summa cum laude, magna cum laude), and 10 MD students with clinical work (1 x magna cum laude, 9 x cum laude), 8 MD students currently ongoing (7 experimental work in the lab, 1 clinical study).

- **Supervision of Master students and Bachelor Students**

4 Master theses completed, 7 Bachelor theses completed

## Scientific Results

### Category A: Ten selected publications as main author

\* First author, \*\* senior author, [OA]: open access

1. \*\* Haeusser LA, Becker H, Kuhlburger L, Zago M, Walter B, Tsiami F, Erdmann S, Trampert J, Surender S, Stahl A, Templin M, Wegner E, Schmidt T, Schmees C, Casadei N, Sevenich L, Claassen M, Nahnsen S, Beck S, Merk DJ, **Tabatabai G**. "Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma".

**Neuro Oncol.** **2025**; 27(4):916-931. doi: 10.1093/neuonc/noae278. [OA]

2. \*\* Merk DJ, Tsiami F, Hirsch S, Walter B, Haeusser LA, Maile JD, Stahl A, Jarboui MA, Lechado-Terradas A, Klose F, Babaei S, Admard J, Casadei N, Roggia C, Spohn M, Schittenhelm J, Singer S, Schüller U, Piccioni F, Persky NS, Claassen M, Tatagiba M, Kahle PJ, Root DE, Templin M, **Tabatabai G**. "Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors".

**Genome Biol.** **2024**; 25(1):301. doi: 10.1186/s13059-024-03438-w. [OA]

3. \*\* Merk DJ, Paul L, Tsiami F, Hohenthanner H, Kouchesfahani GM, Haeusser LA, Walter B, Brown A, Persky NS, Root DE, **Tabatabai G**. "CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines".

**Genome Med J.** **2024**; 16(1):82. doi: 10.1186/s13073-024-01341-4 [OA]

4. \*\* Walter B, Hirsch S, Kuhlburger L, Stahl A, Schnabel L, Wisser S, Haeusser LA, Tsiami F, Plöger S, Aghaallaei N, Dick AM, Skokowa J, Schmees C, Templin M, Schenke-Layland K, Tatagiba M, Nahnsen S, Merk DJ, **Tabatabai G**. "Functionally-instructed modifiers of response to ATR inhibition in experimental glioma".

**Journal of Experimental & Clinical Cancer Research.** **2024**; 43(1):77. doi: 10.1186/s13046-024-02995-z [OA]

5. \*\* Trautwein C, Zizmare L, Mäurer I, Bender B, Bayer B, Ernemann U, Tatagiba M, Grau SJ, Pichler BJ, Skardelly M, **Tabatabai G**. "Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment".

**JCI Insight.** **2022**; 7(3). doi: 10.1172/jci.insight.153526. [OA]

6. \*\* Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M; International Consortium on Meningiomas; Schittenhelm J<sup>§</sup>,

**Tabatabai G<sup>§</sup>.** "H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort".

**Neuro-Oncology, 2021; 23(8): p. 1273-81.** doi: 10.1093/neuonc/noaa303. [OA] (◊co-senior authors)

7. \*\* Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Peña C, **Tabatabai G.** "Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors".  
**Clinical Cancer Research, 2021; 27(10): p. 2723-33.** doi: 10.1158/1078-0432.Ccr-20-4256
8. \* Weller M<sup>◊</sup>, **Tabatabai G<sup>◊</sup>**, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G<sup>§</sup>, Wick W<sup>§</sup>. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.  
**Clinical Cancer Research, 2015; 21(9): p. 2057-64.** doi: 10.1158/1078-0432.Ccr-14-2737 (◊co-shared first authors, §co-shared senior authors)
9. \*\* Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, **Tabatabai G.** "Thymosin  $\beta$  4 gene silencing decreases stemness and invasiveness in glioblastoma".  
**Brain, 2014; 137(Pt 2): p. 433-48.** doi: 10.1093/brain/awt333
10. \*\* Hasenbach K, Wiehr S, Herrmann C, Mannheim J, Cay F, von Kürthy G, Bolmont T, Grathwohl SA, Weller M, Lengerke C, Pichler BJ, **Tabatabai G.** "Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography".  
**Neuro-Oncology, 2012; 14(4): p. 471-81.** doi: 10.1093/neuonc/nor228

## Category B

Ongoing Patent Applications: ENFORCING-GB (5402P681), UNRAVEL-GB (5402P686), IMPACT-GB (5402P687), INTERVENE-GB (5402P690), INTEGRATE (5402P672EP), Therapeutic Agent for Cancer MeP-Gli-01 (5402P578EP)